The DOI matches its Crossref record.
New Therapies for Hepatitis C Virus Infection
Abstract
Chronic hepatitis C virus (HCV) infection remains a global health threat with approximately 175 million carriers worldwide. Currently, treatment consists of pegylated interferon alpha plus ribavirin for 12-72 weeks, depending on HCV genotype, baseline viral load, and initial virological response to therapy. Serious adverse effects and limited sustained virological responses with this therapy warrant the need for novel HCV therapies. Specifically targeted antiviral therapies designed to inhibit the HCV serine protease and the RNA-dependent RNA polymerase have recently entered clinical development. Herein, the main characteristics of these new antiviral agents and the most important challenges arising with their use--namely, toxicities and rapid selection of resistance--are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Comprehensive Review in Current Developments of Benzimidazole‐Based Medicinal Chemistry
Keri, R. S., Hiremathad, A., Budagumpi, S., & Nagaraja, B. M. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12462 · Cited by 394
Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A. J., & Murphy, M. P. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02250.x · Cited by 379
Hepatitis C virus resistance to protease inhibitors
Halfon, P., & Locarnini, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.011 · Cited by 305
COVID-19: Characteristics and Therapeutics
Chilamakuri, R., & Agarwal, S. (2021) · Cells · doi:10.3390/cells10020206 · Cited by 282
Regulation of hepatic innate immunity by hepatitis C virus
Horner, S. M., & Gale, M. (2013) · Nature Medicine · doi:10.1038/nm.3253 · Cited by 278
Metadata
- Authors
- Soriano, V., Peters, M. G., & Zeuzem, S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-02
- Volume
- 48
- Issue
- 3
- Pages
- 313-320
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2103882722
- Cited by
- 168
- References
- 0
- FWCI
- 19.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Therapies for Hepatitis C Virus Infection. https://app.cochat.ai/papers/10.1086/595848
- The paper
- Soriano, V., Peters, M. G., & Zeuzem, S. (2009). New Therapies for Hepatitis C Virus Infection. Clinical Infectious Diseases. https://doi.org/10.1086/595848
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.